A phase i trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study

Kathleen N. Moore, Michael W. Sill, David S. Miller, Carolyn McCourt, Koen De Geest, Peter G. Rose, Higinia R. Cardenes, Robert S. Mannel, John H. Farley, Russell J. Schilder, Paula M. Fracasso

Research output: Contribution to journalArticle

30 Scopus citations

Abstract

Background: Epithelial growth factor receptor over-expression correlates with poor outcomes in cervical cancer. This study assessed the safety of chemoradiation with cetuximab in the treatment of women with newly diagnosed locally advanced cervical cancer. Methods: Patients received weekly cisplatin 30 and 40 mg/m2 [dose level (DL) 1 and 2] and cetuximab 400 mg/m 2 loading dose and then 250 mg/m2 for a total of six weeks with radiotherapy (RT). Patients with nodal metastases received extended field radiation therapy (EFRT). At the maximum tolerated dose, feasibility was evaluated in a 20 patient two-stage, sequential design. Results: In patients receiving pelvic RT, seven were treated at DL 1 with one dose-limiting toxicity (DLT) (febrile neutropenia with grade 3 diarrhea) and three at DL 2 with two DLTs (grade 3 rash and delay in RT > 8 weeks). The feasibility phase was opened at DL1. Of the 21 patients treated there was one DLT (grade 4 CVA). Median RT duration was 50 days (range, 42-70). In patients receiving EFRT, nine were treated at DL 1 with 1 DLT (grade 3 mucositis) and 24 in the feasibility phase with eight DLTs [delay in RT > 8 weeks due to toxicity (2) and one each with grade 3 or 4 small bowel obstruction, embolism, mucositis, mucositis with hypokalemia, pain with headache, and platelets with mucositis and headache]. Median EFRT duration was 56 days (range, 36-74). Conclusions: For patients receiving pelvic RT, cisplatin and cetuximab were feasible. For patients receiving EFRT, combination of cisplatin and cetuximab was not feasible.

Original languageEnglish (US)
Pages (from-to)456-461
Number of pages6
JournalGynecologic oncology
Volume127
Issue number3
DOIs
StatePublished - Dec 2012

Keywords

  • Cervical cancer
  • Cetuximab
  • Pelvic radiation

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'A phase i trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study'. Together they form a unique fingerprint.

  • Cite this

    Moore, K. N., Sill, M. W., Miller, D. S., McCourt, C., De Geest, K., Rose, P. G., Cardenes, H. R., Mannel, R. S., Farley, J. H., Schilder, R. J., & Fracasso, P. M. (2012). A phase i trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study. Gynecologic oncology, 127(3), 456-461. https://doi.org/10.1016/j.ygyno.2012.08.030